Medication-induced labor with prostaglandins in viable fetuses: a 31-month retrospective study in the gynecology and obstetrics department of Amath Dansokho hospital/Kédougou/Senegal
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: To analyze the indications, methods, and outcomes of labor induction with prostaglandins at the Gynecology and Obstetrics Department of Amath Dansokho Regional Hospital in Kédougou, Senegal. Methods: We conducted a retrospective cohort study including 2,750 deliveries from January 1, 2023, to July 31, 2025. All pregnant women ≥28 weeks receiving prostaglandin-induced labor were included (n=501). Exclusion criteria were intrauterine fetal death, abnormal fetal heart rate on admission, prophylactic cesarean, and incomplete records. Data on sociodemographic, obstetric history, induction indications, induction method, and maternal and neonatal outcomes were analyzed using SPSS 27. Patients were classified as “Exposed” (induced) and “Unexposed” (spontaneous labor). Results: Labor induction frequency was 18.2%. Main indications were post-term pregnancy (29.4%), hypertensive disorders (28.9%), and preventive induction (19.3%). Misoprostol (91.6%) was the primary induction agent, administered vaginally at 25 µg per dose. Induction success was 97.6%. Vaginal delivery occurred in 85% of induced patients, and cesarean section risk was significantly lower compared to spontaneous labor (14.8% vs. 25.9%; RR=0.57, p
Fields of Study & Subjects
Maternal and Perinatal Health Interventions
Reproductive Health and Contraception
Preterm Birth and Chorioamnionitis
Publication details
- Journal / source
- International Journal of Reproduction Contraception Obstetrics and Gynecology
- Volume
- 15
- Issue
- 4
- Pages
- 1154–1161
- Publication date
- 27 March 2026
- Language
- EN